Magnetic carriers: A promising device for targeting drugs into the human body

Current Pharmaceutical Design

Volumn 13, Issue 11, 2007, Pages 1179-1185

  Silva, A K A ^a   Silva, E L ^a   Carrico A S ^a   Egito, E Socrates T ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Biotechnology; Magnetic drug targeting; Magnetic particles

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL; DEXTRAN MAGNETITE; DRUG CARRIER; FERRIC OXIDE; FERRITIN; IRON OXIDE; LIPOSOME; MAGNETITE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; RADIOISOTOPE;

ARTIFICIAL EMBOLISM; BIOTECHNOLOGY; BLOOD RHEOLOGY; CANCER THERAPY; CRYSTAL STRUCTURE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG TARGETING; HYPERTHERMIC THERAPY; MAGNETIC FIELD; MAGNETIC SEPARATION; MAGNETISM; MICROEMULSION; NANOENCAPSULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLARIZATION; POLYMERIZATION; PRIORITY JOURNAL; REACTOR; REVIEW; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

BIOTECHNOLOGY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MAGNETICS;

EID: 34248397673     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618993     Document Type: Review

References (86)

1. Ritter JA, Ebner AD, Daniel KD, Stewart KL. Application of high gradient magnetic separation principles to magnetic drug targeting. J Magn Magn Mater 2004; 280: 184-201.
2. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11: S81-S91.
3. Breimer DD. Future challenges for drug delivery research. Adv Drug Deliv Rev 1998; 33: 265-8.
4. Pusieux F, Treupel LR. Vectorisation et vecteurs de médicaments. STP Pharma Sci 1989; 5: 107-13.
5. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol To 2000; 3: 163-71
6. Millan CG, Marinero MLS, Castaneda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004; 95: 27-49.
7. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid St M 2002; 6: 319-27.
8. Ranney DF. Biomimetic transport and rational drug delivery. Biochem Pharmacol 2000; 59: 105-14.
9. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
10. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000; 60: 6641-8.
11. Voltairas PA, Fotiadis DI, Michalis LK. Hydrodynamics of magnetic drug targeting. J Biomech 2002; 35: 813-21.
12. Alexiou C, Schmidt A, Klein R, Hulin P, Bergemann C, Arnold W. Magnetic drug targeting: Biodistribution and dependency on magnetic field strength. J Magn Magn Mater 2002; 252: 363-6.
13. Kuznetsov AA, Filippov VI, Kuznetsov OA, Gerlivanov VG, Dobrinsky EK, Malashin SI. New ferro-carbon adsorbents for magnetically guided transport of anti-cancer drugs. J Magn Magn Mater 1999; 194: 22-30.
14. Hafeli U, Pauer G, Failing S, Tapolsky G. Radiolabeling of magnetic particles with rhenium-188 for cancer therapy. J Magn Magn Mater 2001; 225: 73-8.
15. Hafeli UO. Magnetically modulated therapeutic systems. Int J Pharm 2004; 277: 19-24.
16. Muller RH, Maassen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 1996; 138: 85-94.
17. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron-oxides for Mr-imaging. Adv Drug Deliv Rev 1995; 16: 321-34.
18. Kaminski MD. Rosengart AJ. Detoxification of blood using injectable magnetic nanospheres: A conceptual technology description. J Magn Magn Mater 2005; 293: 398-403.
19. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. Clinical applications of magnetic drug targeting 2001;95:200-6.
20. Kuznetsov OA, Brusentsov NA, Kuznetsov AA, Yurchenko NY, Osipov NE, Bayburtskiy FS. Correlation of the coagulation rates and toxicity of biocompatible ferromagnetic microparticles. J Magn Magn Mater 1999; 194: 83-9.
21. Lubbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drug-targeting. J Magn Magn Mater 1999; 194: 149-55.
22. Hafeli UO, Pauer GJ. In vitro and in vivo toxicity of magnetic microspheres. J Magn Magn Mater 1999; 194: 76-82.
23. Goodwin S, Peterson C, Hoh C, Bittner C. Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy. J Magn Magn Mater 1999; 194: 132-9.
24. Schutt W, Gruttner C, Teller J, Westphal F, Hafeli U, Paulke B, et al. Biocompatible magnetic polymer carriers for in vivo radionuclide delivery. Artif Organs 1999; 23: 98-103.
25. Bulte JWM, de Cuyper M, Despres D, Frank JA. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. J Magn Magn Mater 1999; 194: 204-9.
26. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications 2005; 26: 3995-4021.
27. Zhang Y, Kohler N, Zhang MQ. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002; 23: 1553-61.
28. Lu YJ, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: Mechanism and therapeutic potential. Adv Drug Deliv Rev 2004; 56: 1161-76.
29. Cullity BD. In: Cullity BD Ed. Introdution to magnetic materials. Massachusetts, Addison-Wesley 1972; 67-8, 410-1.
30. Hafeli UO, Lobedann MA, Steingroewer J, Moore LR, Riffle J. Optical method for measurement of magnetophoretic mobility of individual magnetic microspheres in defined magnetic field. J Magn Magn Mater 2005; 293: 224-39.
31. Furlani EP. Analysis of particle transport in a magnetophoretic microsystem. J Appl Phys 2006; 99: 99-110.
32. Neuberger T. Schopf B, Hofmann H, Hofmann M, von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 2005; 293: 483-96.
33. Holm C, Weis JJ. The structure of ferrofluids: A status report. Curr Opin Colloid Interface Sci 2005; 10: 133-40.
34. Massart R. Preparation of Aqueous Magnetic Liquids in Alkaline and Acidic Media. IEEE Trans Magn 1981; 17: 1247-8.
35. Kim DK, Zhang Y, Voit W, Rao KV, Muhammed M. Synthesis and characterization of surfactant-coated superparamagnetic mono-dispersed iron oxide nanoparticles. J Magn Magn Mater 2001; 225: 30-6.
36. Gribanov NM, Bibik EE, Buzunov OV, Naumov VN. Physicochemical Regularities of Obtaining Highly Dispersed Magnetite by the Method of Chemical Condensation. J Magn Magn Mater 1990; 85: 7-10.
37. Bee A, Massart R, Neveu S. Synthesis of very fine maghemite particles. J Magn Magn Mater 1995; 149: 6-9.
38. Liu ZL, Wang HB, Lu QH, Du GH, Peng, L, Du YQ. Synthesis an characterization of ultrafine well-dispersed magnetic nanoparticles. J Magn Magn Mater 2004; 283: 258-62.
39. Sun YK, Ma M, Zhang Y, Gu N. Synthesis of nanometer-size maghemite particles from magnetite. Colloid Surf A-Physicochem Eng Asp 2004; 245: 15-9.
40. 4 obtained by oxidation of aqueous Fe(II) solutions. J Colloid Interface Sci 1994; 165: 244-52.
41. Qu SC, Yang HB, Ren DW, Kan SH, Zou GT, Li DM, et al. Magnetite nanoparticles prepared by precipitation from partially reduced ferric chloride aqueous solutions. J Colloid Interface Sci 1999; 215: 190-2.
42. Sangregorio C, Wiemann JK, O'Connor CJ, Rosenzweig Z. A new method for the synthesis of magnetoliposomes. J Appl Phys 1999; 85: 5699-701.
43. 4 particles in water-in-oil microemulsions. IEEE T Magn 1992; 28: 3180-2.
44. Lee HS, Lee WC, Furubayashi T. A comparison of coprecipitation with microemulsion methods in the preparation of magnetite. J Appl Phys 1999; 85: 5231-3.
45. Lopez-Perez JA, Lopez-Quintela MA, Mira J, Rivas J. Preparation of magnetic fluids with particles obtained in microemulsions. IEEE Trans Magn 1997; 33: 4359-62.
46. Sun ZX, Su FW, Forsling W, Samskog PO. Surface characteristics of magnetite in aqueous suspension. J Colloid Interface Sci 1998; 197: 151-9.
47. Lopez-Quintela MA. Synthesis of nanomaterials in microemulsions: formation mechanisms and growth control. Curr Opin Colloid Interface Sci 2003; 8: 137-44.
48. Dickson DPE, Walton SA, Mann S, Wong K. Properties of magnetoferritin: A novel biomagnetic nanoparticle. Nanostruct Mater 1997; 9: 595-8.
49. Yamashita I. Fabrication of a two-dimensional array of nanoparticles using ferritin molecule. Thin Solid Films 2001; 393: 12-8.
50. Meldrum FC, Heywood BR, Mann S. Magnetoferritin - In vitro synthesis of a novel magnetic protein. Science 1992; 257: 522-3.
51. Kuznetsov AA, Filippov VI, Alyautdin RN, Torshina NL, Kuznetsov OA. Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti-cancer photodynamic drugs. J Magn Magn Mater 2001; 225: 95-100.
52. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. Physicochemical stability of colloidal lipid particles. Biomaterials 2003; 24: 4283-300.
53. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 1995; 70: 95-111.
54. Landfester K, Ramirez LP. Encapsulated magnetite particles for biomedical application. J Phys Condens Matter 2003; 15: S1345-S61.
55. Babincova M, Cicmanec P, Altanerova V, Altaner C. Babinec P. AC-magnetic field controlled drug release from magnetoliposomes: Design of a method for site-specific chemotherapy. Bioelectrochemistry 2002; 55: 17-9.
56. Babincova M, Sourivong P, Chorvat D, Babinec P. Laser triggered drug release from magnetoliposomes. J Magn Magn Mater 1999; 194: 163-6.
57. Dresco PA, Zaitsev VS, Gambino RJ, Chu B. Preparation and properties of magnetite and polymer magnetite nanoparticles. Langmuir 1999; 15: 1945-51.
58. Saravanan M, Bhaskar K, Maharajan G, Pillai KS. Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres. Int J Pharm 2004; 283: 71-82.
59. Wormuth K. Superparamagnetic latex via inverse emulsion polymerization. J Colloid Interface Sci 2001; 241: 366-77.
60. Hong X, Guo W, Yuang H, Li J, Liu YM, Ma L, et al. Periodate oxidation of nanoscaled magnetic dextran composites. J Magn Magn Mater 2004; 269: 95-100.
61. Lee JW, Isobe T, Senna M. Magnetic properties of ultrafine magnetite particles and their slurries prepared via in-situ precipitation. Colloid Surf A-Physicochem Eng Asp 1996; 109: 121-7.
62. Dumazet-Bonnamour I, Le Perchec P. Colloidal dispersion of magnetite nanoparticles via in situ preparation with sodium polyoxyalkylene di-phosphonates. Colloid Surface A 2000; 173: 61-71.
63. Veiga V, Ryan DH, Sourty E, Llanes F, Marchessault RH. Formation and characterization of superparamagnetic cross-linked high amylose starch. Carbohydr Polym 2000; 42: 353-7.
64. Alexiou C, Arnold W, Hulin P, Klein RJ, Renz H, Parak FG, et al. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J Magn Magn Mater 2001; 225: 187-93.
65. Bergemann C, Muller-Schulte D, Oster J, a Brassard L, Lubbe AS. Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications. J Magn Magn Mater 1999; 194: 45-52.
66. Lee SJ, Jeong JR, Shin SC, Kim JC, Chang YH, Lee KH, et al. Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(D,L-latide-co-glycolide). Colloid Surf A-Physicochem Eng Asp 2005; 255: 19-25.
67. Tartaj P, Morales MP, Gonzalez-Carreno T, Veintemillas-Verdaguer S, Serna CJ. Advances in magnetic nanoparticles for biotechnology applications. J Magn Magn Mat 2005; 290: 28-34.
68. Klem MT, Young M, Douglas T. Biomimetic magnetic nanoparticles. Mat Today 2005; 8: 28-37.
69. Weitschies W, Karaus M, Cordini D, Trahms L, Breitkreutz J, Semmler W. Magnetic marker monitoring of disintegrating capsules. Eur J Pharm Sci 2001; 13: 411-6.
70. Hergt R, Andra W, d'Ambly CG, Hilger I, Kaiser WA, Richter U, et al. Physical limits of hyperthermia using magnetite fine particles. IEEE Trans Magn 1998; 34: 3745-54.
71. Chien CL. Antigranulocytes Magnetic Solids. J Appl Phys 1991; 69: 5267-72.
72. Ma M, Wu Y, Zhou H, Sun YK, Zhang Y, Gu N. Size dependence of specific power absorption of Fe3O4 particles in AC magnetic field. J Magn Magn Mater 2004; 268: 33-9.
73. Babincova M, Leszczynska D, Sourivong P, Babinec P. Selective treatment of neoplastic cells using ferritin-mediated electromagnetic hyperthermia. Med Hypotheses 2000; 54: 177-9.
74. Jordan A, Scholz R, Wust P, Fahling H, Felix R. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater 1999; 201: 413-9.
75. Odenbach S. Magnetic fluids - Suspensions of magnetic dipoles and their magnetic control. J Phys Condens Matter 2003; 15: S1497-S508.
76. Safarik I, Safarikova M. Magnetic nanoparticles and biosciences. Mon Chem 2002; 133: 737-59.
77. Safarik I, Safarikova M. Use of magnetic techniques for the isolation of cells. J Chromatogr B 1999; 722: 33-53.
78. Weitschies W, Hartmann V, Grutzmann R, Breitkreutz J. Determination of the disintegration behavior of magnetically marked tablets. Eur J Pharm Biopharm 2001; 52: 221-6.
79. Liu J, Flores GA, Sheng RS. In-vitro investigation of blood embolization in cancer treatment using magnetorheological fluids. J Magn Magn Mater 2001; 225: 209-17.
80. Sheng R, Flores GA, Liu J. In vitro investigation of a novel cancer therapeutic method using embolizing properties of magnetorheological fluids. J Magn Magn Mater 1999; 194: 167-75.
81. Kim DK, Zhang Y, Kehr J, Klason F, Bjelke B, Muhammed M. Characterization and MRI study of surfactant-coated superparamagnetic nanoparticles administered into the rat brain. J Magn Magn Mater 2001; 225: 256-61.
82. Okuhata Y. Delivery of diagnostic agents for magnetic resonance imaging. Adv Drug Deliv Rev 1999; 37: 121-37.
83. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 2005; 100: 1-11.
84. Isaacson RE. Genomics and the prospects for the discovery of new targets for antibacterial and antifungal agents. Curr Pharm Design 2002; 8(13): 1091-8.
85. Tsujikawa T, Andoh A, Fujiyama Y. Enteral and parenteral nutrition therapy for Crohn's disease. Curr Pharm Design 2003; 9(4): 323-32.
86. Willins DA, Kessler M, Walker SS, Reyes GR, Cottarel G. Genomics strategies for antifungal drug discovery-from gene discovery to compound screening. Curr Pharm Design 2002; 8(13): 1137-54.